What Hemex does

Hemex AG is a Swiss private company headquartered in Liestal, Switzerland, founded in 2015 with a reported headcount of 101-250 employees. Its core functional offering is supporting clients in the development of pharmaceuticals and medical devices, positioning it as a development services and consulting partner for the European biomedical ecosystem. Pricing models, customer segments, and named client logos are not disclosed in available sources, and the revenue model is accordingly characterized as services-based without further granularity.

The firm's technology footprint centers on its participation as a partner in the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) initiative, led by Trinity College Dublin and comprising 26 European partners with a €15.2 million program budget. Within this consortium Hemex contributes to synthetic healthcare data generation and AI tools aimed at diagnostics and personalized medicine, building applied exposure to generative AI for structured biomedical data and predictive analytics for clinical use cases. No standalone product portfolio, patents, certifications, or proprietary datasets are disclosed for Hemex itself.

Capital history includes three funding rounds dated 2015, 2018, and 2021, with only the inaugural 2015 round having a disclosed value (~$110k); subsequent round sizes are unreported. Leadership consists of CEO Pascal Winnen and President of the Board Paul Hadváry. Public ownership, investor composition, and detailed customer relationships remain undisclosed in available sources, constraining further inference about the go-to-market motion and revenue mechanics beyond a services-based model in pharma and medtech development.

Name

Hemex

Website

https://hemex.ch

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Hemex AG is a Swiss firm that helps clients develop pharmaceuticals and medical devices, and participates as a partner in the European SEARCH consortium on synthetic healthcare data generation and AI-driven diagnostics and personalized medicine.

Ownership category

akta.pro rank

Product category

Pharmaceutical and Medical Device Development Services

NAICS

Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Data Platform, BI & Analytics Integration (BPAEAAAI)

Keywords

• Pharmaceutical consulting
• Medical device development
• Drug development services
• Biomedical consulting
• Healthcare innovation services

Headquarters

HQ city

Liestal

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Core offering

Hemex AG is a Swiss-based services company that helps clients develop pharmaceuticals and medical devices. The firm provides development advisory and consulting support to companies in the biomedical ecosystem, and participates in collaborative initiatives such as the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) consortium focused on synthetic healthcare data generation and AI tools for diagnostics and personalized medicine.

Product overview

Hemex appears to be involved as a partner in the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) initiative led by Trinity College Dublin. However, the source data does not provide specific details about Hemex's own product portfolio or service offerings.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Development Services Advisory and development support services that help pharmaceutical clients develop drugs and therapies. Targeted at pharmaceutical companies seeking expertise in drug development.
• Medical Device Development Services Advisory and development support services that help clients develop medical devices. Targeted at medical device companies and innovators in the biomedical ecosystem.
• SEARCH Synthetic Healthcare Data Governance Hub Participative consortium offering involving synthetic healthcare data generation and AI tools for diagnostics and personalized medicine, developed in collaboration with Trinity College Dublin and 26 European partners.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Partnerships

One partnership is on record.

• Trinity College DublinleadStrategic or Co-development Partner · 1 October 2024Trinity College Dublin leads the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) initiative, which aims to accelerate healthcare innovation through synthetic data generation and secure data sharing in the biomedical ecosystem. The initiative focuses on developing AI tools for diagnostics and personalized medicine.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Emerging players

• TriNetX: Health research network enabling real-world data access for clinical research and AI development. Overlaps with Hemex's biomedical data sharing and AI tooling themes, though focused on federated real-world data rather than synthetic data.
• Tempus Labs: AI-driven precision medicine company combining large-scale data with diagnostics and therapeutic development. Overlaps with Hemex's interest in AI tools for diagnostics and personalized medicine, but operates a data-centric product model.
• MDClone: Specializes in synthetic, privacy-safe healthcare data for research and analytics. Direct functional comparable to Hemex's synthetic-data generation capability, with established deployments across hospital systems.
• Owkin: AI-driven biotech using federated learning on patient data to support diagnostics and drug discovery. Comparable to Hemex in combining AI capabilities with pharma/biomedical research customers, though focused on building its own AI products rather than services.
• Syntegra: Specialist in synthetic healthcare data generation for biomedical research and AI development. Most direct functional comparable to Hemex's SEARCH-aligned capability, competing for the same emerging synthetic-data-for-healthcare opportunity.
• Atropos Health: Provides AI-driven access to real-world evidence for clinical and research decisions. Comparable to Hemex's AI-for-healthcare ambition, with a narrower but more productized focus on evidence generation.

Broad incumbents

• ICON plc: Major clinical research and contract development organization serving pharma and medical device developers. Comparable to Hemex in helping clients bring drugs and devices to market, though with a global delivery footprint and broader service portfolio.
• IQVIA: Global leader in life-sciences services, clinical research, and healthcare data analytics. Comparable to Hemex in serving pharma/medical device development clients with data-driven capabilities, but operating at vastly greater scale across the full value chain.
• Charles River Laboratories: Provides research models, discovery, and safety assessment services to pharma and medical device developers. Overlaps with Hemex's life-sciences development services positioning, though focused on early-stage research and preclinical work.
• Medidata Solutions (Dassault Systèmes): Clinical trial data platform used across pharma and medical device development. Comparable to Hemex in serving drug/device developers with data and analytics infrastructure, though embedded into the broader Dassault 3DEXPERIENCE portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks3 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments13 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemex